Assessing the clinical outcome of nab ‐paclitaxel in Chinese patients with advanced non‐small‐cell lung cancer

ConclusionThe nab‐paclitaxel chemotherapy could achieve significant tumour responses and encourage survival in advanced NSCLC patients with tolerable toxicities. Further clinical studies are needed to explore the optimal therapy regimen and target users.

Source: The Clinical Respiratory Journal - October 20, 2015 Category: Respiratory Medicine Authors: Junli Zeng, Jie Yin, Dongmei Yuan, Wen Yang, Wenjun Liang, Guannan Wu, Yong Song Tags: ORIGINAL ARTICLE Source Type: research